Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Mereo BioPharma Group plc has provided updates on its key clinical programs, including the ongoing Phase 3 Orbit study for setrusumab, which is being developed for osteogenesis imperfecta (OI ...

Ultragenyx’s recent meeting focused on setrusumab and the ongoing Phase 3 ORBIT trial. The analyst noted that the company remains confident in the trial’s success, with a second interim ...

Shares of Mereo BioPharma (NASDAQ:MREO) rose 7% Friday after Jefferies initiated coverage of the stock with a buy rating, citing the company’s drug candidates setrusumab and alvelestat.

“Based on the highly promising data from completed studies of setrusumab in OI, including the Phase 2 portion of the Orbit Study, we remain confident in the potential of setrusumab to become the ...

A live audio webcast of the presentation can be accessed through the Investors section of the Company’s web Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 ...

The company also provided key program updates including that the UX143 (setrusumab) Phase 3 Orbit study is progressing with the second interim analysis in mid-2025. “In 2024 we grew our business ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung ...

Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final ...